Atea Pharmaceuticals, Inc.

Atea does not currently sell approved products, so its near-term 'customers' are primarily clinical trial participants, investigators, contract research organizations, and contract manufacturing organizations that enable development. If approved, the end users would be patients with HCV or chronic HEV, while the paying customers would likely be healthcare systems, insurers, and government payors that reimburse antiviral therapy. The company also expects to use commercial collaborators outside the U.S. and potentially third-party commercial infrastructure in the U.S. to reach prescribers and managed care channels. In the current stage, value creation depends on convincing regulators, clinicians, and future payors that its regimens can offer differentiated efficacy, convenience, and cost competitiveness versus existing standards of care.

Atea's strategy is to maximize value by retaining global development rights while advancing a focused antiviral pipeline through late-stage clinical milestones. The company is prioritizing bemnifosbuvir and ruzasvir for HCV, where it seeks a differentiated, short-duration, protease inhibitor-free regimen that can compete on convenience and efficacy. It is also advancing AT-587 in HEV, which broadens the pipeline beyond HCV and creates a second potential value driver. Because Atea has no commercial infrastructure, it plans to use collaborators and third-party commercialization capabilities rather than build a large internal sales force, which keeps fixed costs lower but increases dependence on partners and execution quality.